Jump to navigation
Is there a place for actuaries in a world typically dominated by researchers, academics, and policy wonks? Join us on September 18 to find out!
In a perspective piece in the New England Journal of Medicine, CP3 Director Walid Gellad and HPI Director Everette James describe the controversy surrounding the 340B Drug Pricing Program.Read more.
In a recent article in JAMA, researchers compared prescription opioid use and medication-assisted treatment rates before and after an overdose.
In a recent perspective piece in NEJM, Dr. Gellad discusses the accelerated approval process in the era of expensive drugs. Read more.
In a commentary in JAMA Internal Medicine, Dr. Walid Gellad discusses the opioid epidemic within the Nation's Veteran population.
Each year the United States experiences a shortage of over 100 drugs. In an editorial in JAMA, Drs. Donohue and Angus explore the reasons.